Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 1.00 |
| ▸ | BCHE | P06276 | 3/20 | 0.88 |
| ▸ | GABRP | O00591 | 1/20 | 0.88 |
| ▸ | GABRD | O14764 | 1/20 | 0.88 |
| ▸ | APP | P05067 | 1/20 | 0.88 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.88 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.88 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.88 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.88 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.88 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.88 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.88 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.88 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.88 |
| ▸ | BACE1 | P56817 | 1/20 | 0.88 |
| ▸ | GABRE | P78334 | 1/20 | 0.88 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.88 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.88 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.88 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5486217 | 1.00 | ACHE (1.00) | ACHEBCHEGABRPGABRDAPP | |
| SCHEMBL5945380 | 1.00 | ACHE (1.00) | ACHEBCHEGABRPGABRDAPP | |
| SCHEMBL1537859 | 1.00 | ACHE (1.00) | ACHEBCHEGABRPGABRDAPP | |
| SCHEMBL5945371 | 1.00 | ACHE (1.00) | ACHEBCHEGABRPGABRDAPP | |
| SCHEMBL5485655 | 0.99 | ACHE (0.97) | ACHEBCHE | |
| SCHEMBL27855737 | 0.96 | ACHE (0.93) | ACHEBCHEGABRPGABRDAPP | |
| SCHEMBL5487643 | 0.95 | ACHE (0.90) | ACHEBCHE | |
| SCHEMBL24164216 | 0.94 | ACHE (1.00) | ACHEBCHEGABRPGABRDAPP | |
| SCHEMBL15168191 | 0.94 | ACHE (1.00) | ACHEBCHEGABRPGABRDAPP | |
| SCHEMBL29486236 | 0.94 | ACHE (1.00) | ACHEBCHEGABRPGABRDAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2818467-A1 | Multi-target drug compounds for the treatment of neurodegenerative disorders | Universitat de Barcelona (ES) | 2014-12-31 | — | — | EP | disclosed |
| US-20070299093-A1 | Organic Compounds Useful for the Treatment of Alzheimer's Disease, Their Use and Method of Preparation | Alma Mater Studiorum-Universitá Di Bologna (IT) | 2007-12-27 | — | — | US | disclosed |
| US-7307083-B2 | Tetrahydro-acridine and dithiolane derivatives | ALMA MATER STUDIORUM-UNIVERSITA'DI BOLOGNA (IT) | 2007-12-11 | — | — | US | disclosed |
| US-20070219241-A1 | Organic Compounds Useful For The Treatment Of Alzheimer's Disease, Their Use And Method Of Preparation | ALMA MATER STUDIORUM-UNIVERSITA'DI BOLOGNA (IT) | 2007-09-20 | — | — | US | disclosed |
| EP-1558255-B1 | DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | NEUROPHARMA SA (ES) | 2006-12-27 | — | — | EP | disclosed |
| US-20060142323-A1 | Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease | NEUROPHARMA, S.A. (ES) | 2006-06-29 | — | — | US | disclosed |
| EP-1558255-A2 | DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Neuropharma, S.A. (ES) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004032929-A2 | DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | NEUROPHARMA, S.A. (ES) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219241-A1 | Organic Compounds Useful For The Treatment Of Alzheimer's Disease, Their Use And Method Of Preparation | OTC, PSEN2, PSEN1 | ACHE 5/4885BCHE 7/4885GABRP 1701/4885 |
| US-20060142323-A1 | Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease | ACHE, PSEN2, CHAT | ACHE 1/4885BCHE 7/4885GABRP 1298/4885 |
| US-20070299093-A1 | Organic Compounds Useful for the Treatment of Alzheimer's Disease, Their Use and Method of Preparation | OTC, PSEN2, PSEN1 | ACHE 5/4885BCHE 7/4885GABRP 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.